Bluebird Bio Net Profit Margin 2012-2022 | BLUE
Bluebird Bio net profit margin from 2012 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
| Bluebird Bio Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2022-09-30 |
$0.01B |
$-0.45B |
-7566.67% |
| 2022-06-30 |
$0.01B |
$-0.59B |
-8485.71% |
| 2022-03-31 |
$0.01B |
$-0.74B |
-14720.00% |
| 2021-12-31 |
$0.00B |
$-0.82B |
-20500.00% |
| 2021-06-30 |
$0.02B |
$-0.84B |
-4215.00% |
| 2021-03-31 |
$0.22B |
$-0.62B |
-284.02% |
| 2020-06-30 |
$0.23B |
$-0.65B |
-283.91% |
| 2020-03-31 |
$0.04B |
$-0.83B |
-1881.82% |
| 2019-09-30 |
$0.05B |
$-0.72B |
-1349.06% |
| 2019-06-30 |
$0.06B |
$-0.65B |
-1167.86% |
| 2019-03-31 |
$0.05B |
$-0.60B |
-1184.31% |
| 2018-12-31 |
$0.06B |
$-0.56B |
-1009.09% |
| 2018-09-30 |
$0.04B |
$-0.52B |
-1307.50% |
| 2018-06-30 |
$0.04B |
$-0.46B |
-1269.44% |
| 2018-03-31 |
$0.05B |
$-0.38B |
-848.89% |
| 2017-12-31 |
$0.04B |
$-0.34B |
-933.33% |
| 2017-09-30 |
$0.03B |
$-0.29B |
-852.94% |
| 2017-06-30 |
$0.03B |
$-0.29B |
-1028.57% |
| 2017-03-31 |
$0.01B |
$-0.28B |
-2123.08% |
| 2016-12-31 |
$0.01B |
$-0.26B |
-3757.14% |
| 2016-09-30 |
$0.01B |
$-0.24B |
-3983.33% |
| 2016-06-30 |
$0.01B |
$-0.21B |
-4100.00% |
| 2016-03-31 |
$0.01B |
$-0.20B |
-2475.00% |
| 2015-12-31 |
$0.01B |
$-0.17B |
-1284.62% |
| 2015-09-30 |
$0.02B |
$-0.14B |
-777.78% |
| 2015-06-30 |
$0.02B |
$-0.11B |
-495.65% |
| 2015-03-31 |
$0.02B |
$-0.06B |
-266.67% |
| 2014-12-31 |
$0.02B |
$-0.05B |
-208.33% |
| 2014-09-30 |
$0.02B |
$-0.04B |
-158.33% |
| 2014-06-30 |
$0.02B |
$-0.03B |
-112.50% |
| 2014-03-31 |
$0.02B |
$-0.03B |
-125.00% |
| 2013-12-31 |
$0.02B |
$-0.03B |
-136.84% |
| 2013-06-30 |
$0.01B |
$-0.01B |
-171.43% |
| 2013-03-31 |
$0.00B |
$-0.01B |
-1300.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.521B |
$0.004B |
|
bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.?The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent ?-thalassemia (TDT).
|
